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The objective of this open, multicentre, randomized con­
trolled study in women opting for in-vitro fertilization was 
to compare the occurrence of pain and redness at the 
injection site and of post-injection fever after i.m. injection 
with Humegon (n = 89) or Pergonal (n = 92). Assessments 
were scoring of pain and redness at the injection site and 
of post-injection fever during the next 24 h using self­
administered questionnaires. Injection site pain was 
reported in 48.9% of injections with Humegon and in 
44.9% with Pergonal (P = 0.45). A trend was seen towards 
more redness after Pergonal injection (24.0 versus 15.5%; 
P = 0.08). Post-injection fever was reported in 1.4% with
post-injection fever after i.m. injection with Humegon or 
Pergonal.
Humegon and in 1.1% with Pergonal (P 0.80). It
was concluded that there are no statistically significant 
differences between Humegon and Pergonal after i.m. 
injection with respect to the prevalence of pain and redness
at the injection site and of post-injection fever.
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Introduction
g
intramuscular (i.m.) injections of human menopausal gonado­
trophin (HMG) preparations sometimes cause pain, swelling 
and redness at the injection site (Li and Hindle, 1993; Dore 
etaL,  1994). Until recently, there have been no reasons 
to assume that the commercially available urinary HMG 
preparations, Humegon and Pergonal, differed in the extent to 
which such post-injection reactions occur. However, in 1993 
an Australian survey suggested that the prevalence of pain 
1-3 h after injection was higher with Humegon (59%) than 
with Pergonal (41%) (Gilder et a l ,  1993). If such a difference 
is genuine, this could have clinical implications, and a prospect­
ive, randomized controlled study was performed to investigate 
whether there were differences between the preparations in 
this respect. The objective of this study was to compare the 
occurrence of pain and redness at the injection site and of
Materials and methods
In a multicentre, open, group-comp arati ve study, infertile women 
opting for in-vitro fertilization (IVF) were recruited in 1993 and 1994 
from the IVF units of the participating study centres (in Rotterdam 
and Arnhem) and randomized to either Humegon (NV Organon, Oss, 
the Netherlands) or Pergonal (Ares Serono, Geneva, Switzerland), In 
order to control for possible seasonal effects on the subjective 
experience of pain or differences in attributable characteristics, 
assignment of subjects to each group was done by restricted block 
(2X5 subjects) randomization performed separately in each study 
centre. The study protocol was approved by the local ethics committees 
of the participating study centres and written informed consent was 
obtained from all subjects before inclusion into the study. The study 
was conducted in full compliance with the Declaration of Helsinki 
as well as local rules and regulations.
Both Humegon and Pergonal consisted of freeze-dried HMG 
for i.m. administration, containing urine-derived follicle stimulating 
hormone (FSH) and luteinizing hormone (LH) in a ratio of ~1;1. The 
indicated dosage (75, 150 or 225 IU) was dissolved in 1 ml NaCl 
0.9%. After swabbing with 1% Chlorhexidine solution, HMG injections 
were given in the upper outer quadrant of the gluteus maxi mus 
muscle, using a standard gauge injection needle.
Study subjects were eligible for inclusion if they had a referral for 
IVF, were willing to give written informed consent and were able to 
fill in the questionnaires. Exclusion criteria were ovarian stimulation 
with gonadotrophins within 6 months prior to start of the study, 
contra-indications to the use of gonadotrophins and history of allergic 
reactions following injections of any kind.
The treatment period covered one IVF ovarian stimulation cycle 
and subjects were required to visit the hospital once before the start 
of treatment for instruction on how to fill in the questionnaires, and 
subsequently for each HMG injection given during the treatment 
cycle. The effects of the study medication on occurrence and onset 
of injection site pain (0-1 h, 1-3 h and 3-24 h), injection site redness 
and post-injection fever were assessed by the subjects after each 
injection by means of completing the questionnaires. In addition to 
the assessments performed to study the treatment effect of the study 
medication, at each visit the investigator asked whether the subjects 
had had any other adverse experiences while using the medication.
The primary study end-points were the injection-based rates of 
each of the symptoms (i.e. the percentage of all given injections at 
which a symptom occurred within 24 h after injection), whereas the 
secondary end-points were the patient-based rates (i.e. the percentage 
of patients for whom the symptom occurred within 24 h after at least 
one of the given injections). A power calculation indicated that in 
order to detect a real between-group difference of 20% [which was 
indicated from the Australian survey; Gilder et al (1993)] with a 
probability of 80%, each group should consist of 107 subjects. The 
study end-points were statistically analysed using a randomization
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Figure 1. Distribution of the number of injections per patient according to the study preparation.
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Table I. Baseline characteristics of the study groups (mean ±  SD)
Characteristic Humegon Pergonal
Age (years) 32.0 ±  4.5 32.6 ±  4.5
Systolic blood pressure (mmHg) 113.4 ±  11.4 115.0 ±  10.3
Diastolic blood pressure (mmHg) 1 1 1  ■+* K 7Í *u/l /  t*«* l  t ê t 74.0 ±  8.6
Heart vate (beats per min) 74.1 i  10.K 72.3 ±  9.7
Body height (cm) 168.9 ±  6.7 167.4 ±  11.9
Body weight (kg) 67.6 £  14.4 66.2 ±  11.1
Tabic II, Occurrence and severity of injection site paia, injection site 
redness and post-injection fever
test (primary end-points) or ^ “-analysis (secondary end-points) with 
a  =  0.05. A two-sided /'-value for the actual difference in percentage 
between the groups of <0.05 was considered statistically significant.
Results
In total, 250 subjects were randomized (125 to Humegon and 
125 to Pergonal), of whom 181 were included in analyses (89 
with Humegon and 92 with Pergonal). A total of 69 enrolled 
subjects were not included in the analysis: 34 for administrative 
reasons (20 subjects did not start an IVF cycle within the 
study period and for 14 subjects the questionnaire was missing),
24 due to protocol violations regarding inclusion criteria (e.g. 
gonadotrophin injections within 6 months prior to the study), 
and 11 due to protocol violations during treatment (e.g. 
incorrect injection site). The lower than anticipated number of 
evaluable subjects (107 in each group) resulted in a reduction 
of the power from 80 to 77%.
The study centre in Rotterdam recruited 95 evaluable sub­
jects (43 on Humegon and 52 on Pergonal), whereas the centre 
in Arnhem recruited 86 evaluable subjects (46 on Humegon 
and 40 on Pergonal). There were no remarkable differences 
between the groups with respect to baseline characteristics 
(Table I).
The 181 evaluable patients recorded a total of 1547 injections 
with the study drugs. The mean number of injections in both with Pergonal (not significant). Post-injection fever was 
groups was 8.8 ± 2.5 with Humegon and 8.3 ±  2.5 with reported in 1.4% of injections with Humegon and in 1.1% 
Pergonal. The distribution of the number of injections per with Pergonal (P =  0.80) (Table II). Also, when percentages 
patient over the study preparations did not indicate relevant were based on the number of patients, there were no statistically
Symptom and severity Humegon (n =  783) Pergonal (it ~ 764)
n % /< %
Injection site pain
None 400 51.1 421 55 A
Mild 246 31.4 229 30.0
Moderate 112 14.3 100 13.1
Severe 25 3.2 14 1.8
Injection site redness
No 631 84.5 575 76.0
Yes 116 15.5 182 24.0
Missing 36 — 7 —
Post-injcction fever
No 708 98.6 747 98.9
Raised temperature 0 0.0 4 0.5
Fever (>38°C ) 10 1.4 4 0.5
Tabic III. Onset of injection site pain, injection site redness and post «
injection fever
Symptom onset (h) Humegon Pergonal
n % it %
Injection site pain onset (Humegon n ~= 783; Pergonal n ™ 764)
0-1 240 30.7 137 17.9
1-3 76 9.7 103 13.5
3-24 67 8.6 103 13.5
Injection site redness onset (Humegon n =  747; Pergonal // ~  757)
0-1 38 5.1 35 4.6
1-3 ' 46 6.2 52 6.9
3-24 32 4.3 95 12.6
Post-injection fever onset (Humegon it “  718; Pergonal n -  755)
0-1 5 0.7 3 0.4
1-3 1 0.1 3 0.4
3-24 4 0.6 2 0,3
between-group differences (Figure 1), significant differences between Humegon and Pergonal with
Injection site pain was reported in 48.9%) of injections respect to injection site pain (83.1 versus 81.5%'; P =  0.93),
with Humegon and in 44.9% with Pergonal, which was not injection site redness (29.2 versus 43.5%; P —  0.07) or post-
statistically different between groups (P =  0.45). Redness was injection fever (4.6 versus 5.5%; P =  0.94). 
reported in 15.5% of injections with Humegon and in 24.0% Of the 48.9% of injections with Humegon in which injection
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site pain was reported, onset started usually within 1 h. In the 
Pergonal group, onset seemed somewhat delayed as compared 
to the Humegon group. The onset of injection site redness and 
post-injection fever was more equally distributed over the 24 h 
time-frame which was defined for each injection (Table III).
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Discussion
From this randomized comparative study it can be concluded 
that there are no marked differences between Humegon and 
Pergonal after i.m. injection with respect to injection site pain, 
injection site redness and post-injection fever in patients 
undergoing IVF. The betweeivgroup difference regarding injec­
tion site redness (Pergonal 24.0 versus Humegon 15.5%; P = 
0.08) may indicate a trend, but was not statistically significant.
All analysed injections were given in the buttock, whereas 
in clinical practice HMG injections may also be given in the 
upper thigh. However, this is not thought to have compromised 
the validity of the study results, since there are no indications 
that different skin reactions can be expected between i.m. 
injections in the buttock and upper thigh.
Unlike the results of the Australian survey (Gilder et al ,  
1993), our study did not show significant differences in 
injection site pain between Humegon and Pergonal. Well- 
controlled studies have not previously been performed with 
respect to local reactions after i.m. administration, but these 
preparations have recently been compared in a double-blind 
randomized study (Odink et a l ,  1995) with respect to local 
side-effects after s.c. injection. In that study, local pain was 
not observed with either preparation, but it should be emphas­
ized here that the injected volume was only 0.1 ml. Pergonal- 
treated subjects showed significantly more induration at the 
injection site and greater erythema surfaces than Humegon- 
treated subjects, but the authors could not provide an explana­
tion for the between-group differences (Odink et a l ,  1995).
Both Humegon and Pergonal are comparable with respect 
to the amount and concentration of the active ingredient 
(Stokman et al., 1993). Urinary HMG preparations contain a 
high amount of non-active proteins (~98% of the total protein 
amount) (Editorial, 1992; Biffoni et a l ,  1994), which can give 
rise to local side-effects after injection. In addition, allergic 
skin reactions have been reported after HMG treatment which 
resolved after changing to more purified gonadotrophin pre­
parations (I-Iarika et a l , 1994; Redfearn et al ,  1995). Among 
the proteins that have been identified in urinary HMG prepara­
tions are tumour necrosis factor (TNF)-binding protein-I, 
transferrin and immunoglobulins (Giudice et a l ,  1994). In a 
recent study with a recombinant FSH preparation (follitropin 
beta; Puregon; NV Organon, Oss, The Netherlands) which 
contains no protein contamination (<0.1 %), local side-effects 
were recorded in a similar manner as in this study. The 
incidence of post-injection pain after i.m. injection of Puregon 
was 3 L2%, which seems to be lower than the 45-49% recorded 
in the current study (Out et a l ,  1997).
In conclusion, as far as the occurrence of local side-effects 
after i.m, injection is concerned, there is no reason to prefer 
one urinary HMG preparation over the other.
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